SAB Biotherapeutics, Inc.
Support and Resistance Levels
Past performance
News About SABS
All events for SABS
All deals for SABS
Financial Ratios
Financial Statements
SABS vs Sector & Peers
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. Website sab.bio
Headquarters Miami Beach, FL, US